Under the exclusive agreement, India-based Glenmark has granted Spanish firm Cyndea rights to use its technology for developing capsule formulations of certain pharmaceutical products, in order to develop, license, manufacture and supply these products for commercialisation.
The companies will share developments costs and profits from future sales. In exchange, Glenmark will receive exclusive rights to sell the products in the US and Canada.
A Glenmark spokesperson told us the firm chose Cyndea because it has considerably synergies with regards to generic drug development.
The firm did not disclose which drugs would be manufactured under the agreement.
According to the spokesperson, soft-gelatin capsule formulations are easily absorbed by the body, which can increase the bioavailability of the drug.
“Currently, there are significant challenges with aqueous solubility of small molecule pharmaceutical products, whereas as many as 70 percent are difficult for the body to orally absorb (low bioavailability).”
“Because of this challenge, soft-gelatin capsules have wide applications to improve absorption and bioavailability of these medicines.”
“The agreement allows both companies to leverage their individual strengths to bring much-needed soft-gelatin, oral formulations of small molecule pharmaceuticals to patients worldwide,” the spokesperson told us.